Maze Therapeutics, Inc.
NASDAQMaze Therapeutics delivered a sharp single-session move on Tuesday — the stock jumped nearly 27% to close at $28.38 — driven by a fresh Citigroup coverage initiation that arrived into a tape where shorts already held over 11% of the free float. The Street reaction was swift but not unanimous. Citigroup's Eric Joseph initiated with a Buy and a $50 target on September 23, the most…
MAZE short interest surges 26.5% in one week to 9.1% of float, signaling mounting bearish positioning ahead of earnings Thursday.
Snapshot as of 25 Sept 2026
Maze Therapeutics delivered a sharp single-session move on Tuesday — the stock jumped nearly 27% to close at $28.38 — driven by a fresh Citigroup coverage initiation that arrived into a tape where shorts already held…
Maze Therapeutics reports today with a notable divergence at the heart of its setup: short sellers have been adding positions steadily, yet the lending market remains far from stressed — leaving the real tension…
Maze Therapeutics reports Q1 2026 results on May 14 with short sellers freshly emboldened — and analysts split on how far the MZE829 story can run. The most striking pre-print development is in short positioning. Short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MAZE — free to start on ORTEX.
Sign up for free →Open MAZE on ORTEX